共 50 条
- [11] Single-Center Experience of Axicabtagene Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Large B-Cell LymphomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S267 - S268Melody, MeganRahman, Zaid AbdelErnesto, AyalaGannon, NicoleRoy, VivekSher, TaimurAilawadhi, SikanderForan, JamesDabaja, Mohamed Kharfan
- [12] Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaBLOOD ADVANCES, 2020, 4 (13) : 2871 - 2883Pinnix, Chelsea C.Gunther, Jillian R.Dabaja, Bouthaina S.Strati, PaoloFang, PennyHawkins, Misha C.Adkins, SherryWestin, JasonAhmed, SairahFayad, LuisLee, Hun JuNair, RanjitSteiner, Raphael E.Iyer, Swaminathan P.Rodriguez, M. AlmaWang, MichaelFlowers, ChristopherNeelapu, Sattva S.Nastoupil, Loretta J.
- [13] CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) - the Munich Real Life ExperienceONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 80 - 81Buecklein, V.Schmidt, C.Blumenberg, V.Reischer, A.von, Baumgarten L.Voelkl, A.Wagner, B.Humpe, A.Reilich, S.Bauer, M.Ostermann, H.Tischer, J.Stemmler, H-J.von Bergwelt, M.Subklewe, M.
- [14] Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphomaHEMASPHERE, 2025, 9 (01):Stock, SophiaBucklein, Veit L.Blumenberg, ViktoriaMagno, GiuliaEmhardt, Alica-JoanaHolzem, Alessandra M. E.dos Santos, David M. CordasSchmidt, ChristianGriesshammer, StefanieFrolich, LisaKobold, Sebastianvon Bergwelt-Baildon, MichaelRejeski, KaiSubklewe, Marion
- [15] Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapyBLOOD ADVANCES, 2020, 4 (19) : 4869 - 4872Chow, Victor A.Gopal, Ajay K.Gauthier, JordanTseng, Yolanda D.Turtle, Cameron J.Maloney, David G.Shadman, Mazyar
- [16] CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell LymphomaCLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (06) : 597 - 601Gideon, Jacklyn
- [17] Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell LymphomaCELLS, 2022, 11 (24)Huang, LefuLi, JingjingYang, JunfangZhang, XianZhang, MinHe, JiujiangZhang, GailingLi, WenqianWang, HuiLi, JianqiangLu, Peihua
- [18] Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic responseHAEMATOLOGICA, 2023, 108 (04) : 1163 - 1167Jallouk, Andrew P.Gouni, SushanthWestin, JasonFeng, LeiMistry, HaleighSteiner, Raphael E.James, JinsuNoorani, MansoorHorowitz, SandraPuebla-Osorio, NahumFayad, Luis E.Iyer, Swaminathan P.Hawkins, MishaFlowers, Christopher R.Ahmed, SairahNastoupil, Loretta J.Kebriaei, PartowShpall, Elizabeth J.Neelapu, Sattva S.Nieto, YagoStrati, Paolo
- [19] Prophylactic corticosteroid use with axicabtagene ciloleucel in patients with relapsed/refractory large B-Cell lymphomaBRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 147 - 148Oluwole, Olalekan O.Bouabdallah, KrimoMunoz, JavierDe Guibert, SophieVose, Julie M.Bartlett, Nancy L.Lin, YiDeol, AbhinavMcSweeney, Peter A.Goy, Andre H.Kersten, Marie JoseJacobson, Caron A.Farooq, UmarMinnema, Monique C.Thieblemont, CatherineTimmerman, John M.Stiff, PatrickAvivi, IritTzachanis, DimitriosKim, Jenny J.Bashir, ZahidMcLeroy, JeffGoyal, LovelyJohnson, LisaZheng, Yanvan Meerten, Tom
- [20] Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community OncologistONCOLOGIST, 2020, 25 (01): : E138 - E146Jacobson, Caron A.Farooq, UmarGhobadi, Armin